Record Q4 sales and strong H2 recovery led to positive EBITDA, though annual revenue declined. Strategic investments and a 13 MSEK capital raise supported new product launches and market expansion, with pharma as the main revenue driver and growing recurring service income.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.